Spots Global Cancer Trial Database for QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
Official Title: A Prospective, Randomized, Open-label, Phase II Study of QYHJ Granules Versus Xeloda in the Second-line Treatment of Patients With Metastatic Pancreatic Cancer
Study ID: NCT01796782
Conditions
Study Description
Brief Summary: Primary End Point: - To compare the overall survival (OS) using QYHJ Granules or Xeloda as the second therapy in patients with metastatic pancreatic cancer. Secondary End Points: * Compare clinical efficacy by other measures including PFS,tumor response,and changes in quality of life (QOL) between these two groups. * Examine the feasibility and assess the side effects of treatment using QYHJ Granules in patients with metastatic pancreatic cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: zhen Chen, M.D.
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: lu ming Liu, M.D.
Affiliation: Fudan University
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
